/
KRMD
$4.37-$0.09 (-2.02%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$204.9M
46M shares
52-week range
$2.91 – $6.61
39% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-0.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.4M | $23.2M | $24.2M | $23.5M | $27.9M | $28.5M | $33.6M | $41.1M |
| Cost of revenue | $6.5M | $8.3M | $9.2M | $9.7M | $12.5M | $11.8M | $12.3M | $15.5M |
| Gross profit | $10.8M | $14.9M | $14.9M | $13.8M | $15.4M | $16.7M | $21.3M | $25.6M |
| Gross margin | 62.3% | 64.1% | 61.8% | 58.6% | 55.1% | 58.6% | 63.4% | 62.3% |
| R&D | $241.1K | $740.5K | $1.3M | $2.5M | $5.0M | $5.7M | $5.3M | $4.4M |
| Operating income | $1.2M | $585.7K | −$1.3M | −$7.0M | −$10.8M | −$10.3M | −$6.4M | −$3.0M |
| EBITDA | $2.4M | $4.3M | $1.6M | −$5.9M | −$10.1M | −$8.9M | −$5.3M | −$1.8M |
| Net income | $910.6K | $564.3K | −$1.2M | −$4.6M | −$8.7M | −$13.7M | −$6.1M | −$2.6M |
| Net margin | 5.2% | 2.4% | -5.0% | -19.4% | -31.0% | -48.2% | -18.0% | -6.4% |
| EPS (diluted) | 0.02 | 0.01 | -0.03 | -0.10 | -0.19 | -0.30 | -0.13 | -0.06 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $49M | $-0.04 | $-0.06–$-0.03 | 3 |
| 2027 | $57M | $0.03 | $0.03–$0.03 | 3 |
| 2028 | $64M | $0.10 | $0.10–$0.10 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
KORU Medical Systems, Inc. Common Stock (DE)
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
www.korumedical.com- Employees
- 73
- IPO / List date
- Mar 1, 1996
- HQ
- MAHWAH, NJ
Held by traders on TradeandTell
No one on the platform currently holds KRMD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 45,900 | $198.3K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KRMD yet.
